Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1979 2
1980 1
1982 3
1984 2
1985 4
1986 1
1987 2
1988 3
1989 2
1990 3
1991 2
1992 2
1993 7
1994 5
1995 3
1996 5
1997 4
1998 4
1999 2
2000 6
2001 5
2002 3
2003 5
2004 4
2005 2
2006 2
2007 5
2008 4
2009 3
2010 2
2011 3
2012 1
2013 2
2014 6
2015 6
2016 4
2017 7
2018 3
2019 3
2020 8
2021 4
2022 15
2023 5
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Results by year

Filters applied: . Clear all
Page 1
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study.
Katsumata Y, Inoue E, Harigai M, Cho J, Louthrenoo W, Hoi A, Golder V, Lau CS, Lateef A, Chen YH, Luo SF, Wu YJ, Hamijoyo L, Li Z, Sockalingam S, Navarra S, Zamora L, Hao Y, Zhang Z, Chan M, Oon S, Ng K, Kikuchi J, Takeuchi T, Goldblatt F, O'Neill S, Tugnet N, Law AHN, Bae SC, Tanaka Y, Ohkubo N, Kumar S, Kandane-Rathnayake R, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration. Katsumata Y, et al. Among authors: ohkubo n. Ann Rheum Dis. 2024 Jul 15;83(8):998-1005. doi: 10.1136/ard-2023-225369. Ann Rheum Dis. 2024. PMID: 38423757
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J, Shen L, Huq M, Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Hamijoyo L, Luo SF, Wu YJ, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake D, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Navarra SV, Lau CS, Hoi A, Morand EF, Nikpour M, Lateef A; Asia-Pacific Lupus Collaboration. Cho J, et al. Among authors: ohkubo n. Lancet Rheumatol. 2023 Oct;5(10):e584-e593. doi: 10.1016/S2665-9913(23)00209-6. Epub 2023 Sep 12. Lancet Rheumatol. 2023. PMID: 38251484
Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.
Sonomoto K, Nakayamada S, Fujino Y, Miyata H, Kubo S, Fujita Y, Inoue Y, Matsunaga S, Iwata S, Hanami K, Todoroki Y, Yoshinari-Korekoda H, Kawabe A, Yamaguchi A, Ueno M, Satoh-Kanda Y, Kanda R, Funada M, Ohkubo N, Kusaka K, Kosaka S, Nagayasu A, Fukuyo S, Nawata M, Miyazaki Y, Tokunaga M, Tanaka K, Okada Y, Tanaka Y. Sonomoto K, et al. Among authors: ohkubo n. Rheumatology (Oxford). 2024 Aug 1;63(8):2239-2248. doi: 10.1093/rheumatology/kead579. Rheumatology (Oxford). 2024. PMID: 37934120
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.
Golder V, Kandane-Rathnayake R, Li N, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake D, Chan M, Kikuchi J, Takeuchi T, Bae SC, Goldblatt F, Oon S, O'Neill S, Ng K, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Lau CS, Hoi A, Nikpour M, Morand EF; Asia Pacific Lupus Collaboration. Golder V, et al. Among authors: ohkubo n. Lancet Rheumatol. 2024 Aug;6(8):e528-e536. doi: 10.1016/S2665-9913(24)00121-8. Epub 2024 Jun 11. Lancet Rheumatol. 2024. PMID: 38876129
Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis.
Iwata S, Zhang M, Hajime M, Ohkubo N, Sonomoto K, Torimoto K, Kitanaga Y, Trimova G, Todoroki Y, Miyata H, Ueno M, Nagayasu A, Kanda R, Nakano K, Nakayamada S, Sakata K, Tanaka Y. Iwata S, et al. Among authors: ohkubo n. Rheumatology (Oxford). 2021 Nov 3;60(11):5452-5462. doi: 10.1093/rheumatology/keab229. Rheumatology (Oxford). 2021. PMID: 33693564
157 results